A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors.
Anaplastic Lymphoma Kinase
/ antagonists & inhibitors
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ administration & dosage
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Choroid Neoplasms
/ diagnostic imaging
Female
Humans
Lung Neoplasms
/ drug therapy
Middle Aged
Paclitaxel
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
entrez:
6
12
2019
pubmed:
6
12
2019
medline:
21
10
2020
Statut:
ppublish
Résumé
Choroidal localization from non-small cell lung cancer is rare and when it occurs may cause visual alterations. Targeted therapy against actionable gene mutations represents the standard of care in advanced non-small cell lung cancer. We report the case of a 53-year-old woman affected by metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who received ALK tyrosine kinase inhibitors, from January 2017. The patient had a complete response of choroidal metastasis after therapy with ALK tyrosine kinase inhibitors. She recovered a complete visus and actually she still continue therapy with alectinib. The patient had a complete recovery of visus in addiction to a long response on treatment.
Identifiants
pubmed: 31804301
doi: 10.1097/CAD.0000000000000848
pii: 00001813-202001000-00014
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Paclitaxel
P88XT4IS4D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-94Références
Kanthan GL, Jayamohan J, Yip D, Conway RM. Management of metastatic carcinoma of the uveal tract: an evidence-based analysis Clin Exp Ophthalmol. 2007; 35:553–565
Shah SU, Mashayekhi A, Shields CL, Walia HS, Hubbard GB, Zhang J, et al. Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients Ophthalmology. 2014; 390:29–39
Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases Ophthalmology. 1997; 104:1265–1276
Demirci H, Shields CL, Chao AN, Shields JA. Uveal metastasis from breast cancer in 264 patients Am J Ophthalmol. 2003; 136:264–271
Funazo T, Morita K, Ikegami N, Konishi C, Nakao S, Ariyasu R, et al. Successful treatment with alectinib for choroidal metastasis in anaplastic lymphoma kinase rearranged non-small cell lung cancer Intern Med. 2017; 56:2317–2320
Feng Y, Singh AD, Lanigan C, Tubbs RR, Ma PC. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry J Thorac Oncol. 2013; 8:e109–e111
Singh N, Kulkarni P, Aggarwal AN, Rai Mittal B, Gupta N, Behera D, Gupta A. Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature Medicine (Baltimore). 2012; 91:179–194
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med. 2013; 368:2385–2394
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Lancet. 2017; 390:29–39